EUVIMEDEUVIMED entdecken
Open Access

Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia

Gomerčić Palčić Marija, Matijaca Hana, Kruljac Ivan, Vusić Lucija, Hostić Vedran, Vrbanić Luka, Fanika Mrsić, Zrilić Radovan, Ćelap Ivana, Gaćina Petar

Biochemia medica · 2023

DOI: 10.11613/bm.2023.020704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemia medica, 2023. Verfasst von Gomerčić Palčić Marija und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of Zagreb, Zagreb, Croatia. Hauptthemen laut MEDLINE: Neutrophils, COVID-19. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IntroductionTocilizumab is used in patients with severe COVID-19 pneumonia and high concentration of IL-6. We studied potential prognostic role of neutrophil and lymphocyte count regarding tocilizumab treatment. Materials and methodsWe enrolled 31 patients with severe COVID-19 pneumonia and higher serum IL-6 concentration. The samples were taken on the day of tocilizumab administration and five days later. We used ROC analysis to investigate the association between the analysed parameters and 30-day mortality in order to determine the best pre-treatment and post-treatment prognostic factor. Kaplan-Meier curves and log-rank test were used to present and to analyse the difference in survival. ResultsPatients had a median age of 63 (55-67) years and were treated with a median tocilizumab dose of 800 mg. During the 30-day follow-up period, 17 patients died (30-day mortality 54%). Among pre-treatment variables, neutrophil count had the best prognostic accuracy (AUC 0.81, 95%CI: 0.65-0.96, P = 0.004), while neutrophil to lymphocyte ratio (NLR) had the highest accuracy among post-treatment variables in predicting 30-day mortality (AUC 0.94, 95%CI: 0.86-1.00, P < 0.001). Among post-treatment parameters, neutrophil count and NLR were equally good prognostic factors. Post-treatment NLR cut-off of 9.8 had the sensitivity of 81% and specificity of 93%. Patients with NLR ≥ 9.8 had the median survival of 7.0 (3-10) days vs. median survival not reached in patients with NLR < 9.8 (P < 0.001) ConclusionPre-treatment and post-treatment neutrophil count with post-treatment NLR may represent prognostic tools for patients with higher IL-6 concentration in severe COVID-19 pneumonia treated with tocilizumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeutrophilsCOVID-19HumansMiddle AgedAgedPrognosisInterleukin-6Retrospective StudiesCOVID-19 Drug TreatmentLymphocytesROC CurveAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

COVID-19interleukin-6lymphocytesneutrophilstocilizumab

Substanzen

Interleukin-6tocilizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Pulmonology, Zagreb, Croatia.
  • Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Hematology, Zagreb, Croatia.
  • Solmed Group, Department: Poliklinika Solmed, Zagreb, Croatia.
  • Department of Anesthesiology, Intensive Care Medicine and Pain Management, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
  • Department of Internal Medicine, Sestre milosrdnice University Hospital Center, Division of Clinical Immunology and Rheumatology, Zagreb, Croatia.

Zitieren

APA

Palčić Marija, G., Hana, M., Ivan, K., Lucija, V., Vedran, H., Luka, V., Mrsić, F., Radovan, Z., Ivana, Ć., & Petar, G. (2023). Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia. Biochemia medica. https://doi.org/10.11613/bm.2023.020704

Vancouver

Palčić Marija G, Hana M, Ivan K, Lucija V, Vedran H, Luka V, et al. Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia. Biochemia medica. 2023. doi:10.11613/bm.2023.020704

BibTeX
@article{PaliMarija2023,
  author = {Palčić Marija, Gomerčić and Hana, Matijaca and Ivan, Kruljac and Lucija, Vusić and Vedran, Hostić and Luka, Vrbanić and Mrsić, Fanika and Radovan, Zrilić and Ivana, Ćelap and Petar, Gaćina},
  title = {Post-treatment neutrophil to lymphocyte ratio as a prognostic tool in patients treated with tocilizumab for severe COVID-19 pneumonia},
  journal = {Biochemia medica},
  year = {2023},
  doi = {10.11613/bm.2023.020704}
}
Kostenlos starten →